Denosumab (Prolia, Xgeva) and Denosumab Biosimilars notification
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for denosumab products and biosimilars for Blue Cross Blue Shield North Carolina members, covering osteoporosis, cancer-related indications, giant cell tumor of bone, hypercalcemia of malignancy, and related uses.
Added Bildyos (denosumab-nxxp) to preferred Prolia biosimilars and Bilprevda (denosumab-nxxp) to preferred Xgeva biosimilars and updated preferred/non-preferred lists.
Removed required trial of IV bisphosphonate for certain breast and lung cancer bone metastases indications for Xgeva products and added other indication expansions and restrictions (e.g., castration-resistant prostate cancer, systemic mastocytosis).
Added Site of Care Medical Necessity Criteria specifying when inpatient or outpatient hospital administration is allowed and alternatives if criteria are not met.
Updated HCPCS/Coding table: added Q5157, Q5158, Q5159 for specific biosimilars and removed miscellaneous J/C codes for some products.
Coverage and Medical Necessity Criteria
Medical necessity — general and indication-specific
Covered when ALL of the following are met (structure varies by indication — nested AND/OR logic follows):
Root
Age and primary diagnosis
- Osteoporosis population requirement: For osteoporosis: patient is a male over 50 OR postmenopausal female
- High fracture risk defined by history of osteoporotic fracture OR multiple risk factors for fracture
- Prior bisphosphonate criteria: Either prior bisphosphonate therapy with therapeutic failure/inadequate response OR contraindication/hypersensitivity to bisphosphonates
- Cancer and other indications: For cancer-related and other indications: indication-specific requirements such as current therapy (e.g., aromatase inhibitor for breast cancer; androgen deprivation therapy for nonmetastatic prostate cancer), documented bone metastases when required, prior IV bisphosphonate failure or intolerance where specified, and age limits for giant cell tumor (>=12 years and skeletally mature)
- Biosimilar preference exceptions: If request is for a non-preferred denosumab product, patient must have tried and had inadequate response to all listed preferred biosimilars OR have intolerance/FDA contraindication/hypersensitivity to those preferred biosimilars OR have a documented serious adverse event to the preferred biosimilars with submission of an FDA MedWatch form
- Concomitant therapy exclusion: Patient will NOT be using the requested agent in combination with a bisphosphonate, another denosumab product, romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis
- Quantity and site-of-care: Requested quantity does not exceed maximum units for duration of approval and for inpatient or outpatient hospital administration the Site of Care Criteria apply
Site of Care Medical Necessity Criteria
Administration in inpatient or outpatient hospital setting is allowed only when specified conditions are met; otherwise administration should occur in home or physician office.
Biosimilar trial-and-failure criteria
Coverage for non-preferred denosumab biosimilars requires documented trial and failure of specified preferred biosimilars or documented serious adverse events to preferred biosimilars with supporting MedWatch reporting.
Coverage is not allowed when the requested denosumab product is to be used concomitantly with other bone-active agents. Specifically, the patient will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab (for example, Prolia or Xgeva), romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis (e.g., abaloparatide, teriparatide).
For all restricted denosumab products and indications, the policy prohibits use in combination with other denosumab formulations. Requests for a restricted product will be denied if the patient is receiving or intends to receive another form of denosumab (e.g., Prolia or Xgeva) concurrently; this prohibition is applied uniformly across the restricted product list and indications.
Requests that do not meet the diagnosis-specific medical necessity criteria, the required prior therapy or step-therapy conditions, or that lack documentation of intolerance/contraindication or required adverse-event reporting will be considered not medically necessary and denied. Additionally, requests exceeding the maximum units allowed for the approved duration or lacking required medical-record documentation (e.g., trials and inadequate response, MedWatch submission when applicable) will be denied.
Administration in the inpatient setting solely for the purpose of giving the denosumab injection or infusion does not meet Site of Care Medical Necessity Criteria. Inpatient administration is permitted only when the medical necessity criteria are met and the inpatient admission is not for the sole purpose of administering the injection/infusion; otherwise the drug should be administered in a home-based infusion or physician office setting.
HCPCS, J-codes, ICD-10 and Unit Limits
| J0897 | denosumab (Prolia) subcutaneous (SC) injection |
| Q5136 | denosumab-bbdz (Jubbonti) subcutaneous (SC) injection |
| Q5157 | denosumab-bmwo (Stoboclo) subcutaneous (SC) injection |
| Q5158 | denosumab-bnht (Conexxence) subcutaneous (SC) injection |
| Q5159 | denosumab-dssb (Ospomyv) / denosumab-kyqq (Bosaya) subcutaneous (SC) injection |
| C9399 | Not otherwise classified HCPCS used for some biosimilars |
| J3490 | Unclassified drugs HCPCS used for some biosimilars |
| J3590 | Unclassified biologics HCPCS used for some biosimilars |
| J0897 | denosumab (Xgeva) subcutaneous (SC) injection |
| Q5136 | denosumab-bbdz (Wyost) subcutaneous (SC) injection |
| Q5157 | denosumab-bmwo (Osenvelt) subcutaneous (SC) injection |
| Q5158 | denosumab-bnht (Bomyntra) / Conexxence subcutaneous (SC) injection |
| Q5159 | denosumab-dssb (Xbryk) subcutaneous (SC) injection |
| C9399 / J3490 / J3590 / J9999 | Previously used miscellaneous HCPCS/J-codes for several biosimilars |
| C00.0-C49.9, C4A.0-C4A.9, C50.011-C79.9, C7A.00-C7A.8, C7B.00-C7B.8, C80.0-C86.6, C88.2-C96.Z, D00.00-D09.9, M81.0, M81.8, T50.905, Z51.11, Z51.12, Z79.811, Z87.311 | ICD-10 codes listed as applicable; cancer diagnosis code must accompany certain codes for oncology use |
Prior Authorization, Step Therapy, and Documentation Requirements
Prior Authorization Required
Prior authorization is required for all requests for restricted denosumab products. Authorizations may be issued for up to 365 days (1 year).
- Effective Date: 2026-01-01
- Duration of approval: 365 days (1 year)
Biosimilar Step Therapy Required
Step therapy is required between preferred and non-preferred denosumab biosimilar products. For requests for non-preferred Prolia (denosumab) biosimilars, the patient must have tried and had an inadequate response to ALL specified preferred Prolia biosimilars (examples include Bildyos, Jubbonti, and Stoboclo) or have documented intolerance/contraindication or a documented serious adverse event to those preferred products. For requests for non-preferred Xgeva (denosumab) biosimilars, the patient must have tried and had an inadequate response to ALL specified preferred Xgeva biosimilars (examples include Bilprevda, Osenvelt, and Wyost) or have documented intolerance/contraindication or a documented serious adverse event to those preferred products.
- Preferred Prolia biosimilars to try first: Bildyos (denosumab-nxxp), Jubbonti (denosumab-bbdz), Stoboclo (denosumab-bmwo)
- Preferred Xgeva biosimilars to try first: Bilprevda (denosumab-nxxp), Osenvelt (denosumab-bmwo), Wyost (denosumab-bbdz)
Required Documentation
Medical record documentation is required to demonstrate trials and inadequate response to preferred denosumab biosimilars or IV bisphosphonates, as applicable, or documentation of intolerance/contraindication. Requests must also include documentation that the requested agent will not be used in combination with a bisphosphonate, another form of denosumab, romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis.
- Medical record documentation of trial and inadequate response to ALL listed preferred biosimilars is required.
- Documentation of intolerance, FDA labeled contraindication, or hypersensitivity to preferred biosimilars is required when claimed.
- Documentation that the requested agent will NOT be used in combination with bisphosphonates, another denosumab, romosozumab-aqqg, or parathyroid hormone analogs.
Adverse Event Documentation for Non‑Preferred Biosimilar Exception
When requesting an exception based on a documented serious adverse event to preferred biosimilars, the prescriber must complete and submit an FDA MedWatch Adverse Event Reporting Form and include this submission in the medical record documentation.
- Submit completed FDA MedWatch Adverse Event Reporting Form when serious adverse event is cited
- Document the adverse event in the medical record and show it required medical intervention and is not anticipated with the requested agent
Denial Triggers
Requests will be denied if medical necessity criteria are not met. Common denial triggers include failure to meet age or diagnosis requirements, lack of documented high fracture risk (for osteoporosis indications), absence of required trial and failure of preferred biosimilars or IV bisphosphonates where specified, use in combination with excluded agents, exceeding maximum allowed units, or missing required documentation.
- Denial triggers: unmet age/diagnosis criteria, no high fracture risk documentation, no documented trial/failure of preferred products, concurrent use with excluded agents, request exceeds maximum units
- Missing FDA MedWatch form or inadequate adverse event documentation may result in denial
Site‑of‑Care Denial Risk
Site of Care criteria apply for injection or infusion administration in inpatient or outpatient hospital settings. Requests for hospital-based administration that do not meet the Site of Care Medical Necessity Criteria will be denied and the administration should be provided in a home-based infusion or physician office setting where criteria are not met.
- Inpatient: administration allowed only if medical necessity met and admission is not solely for administration
- Outpatient hospital: one of listed Site of Care criteria must be met (e.g., history of severe adverse event, conditions increasing risk, inability to adhere to regimen, new to therapy, re-initiation, or change in product formulation)
- If Site of Care criteria are not met, administration must occur in home infusion or physician office setting
Background and Clinical Context
Denosumab products are indicated for multiple bone-related conditions. The policy covers denosumab formulations for the treatment of osteoporosis in adults at high fracture risk (including postmenopausal women and men >50), and for oncologic and related indications including prevention of skeletal-related events in multiple myeloma and bone metastases from solid tumors, treatment of giant cell tumor of bone (age and skeletal maturity criteria apply), and management of hypercalcemia of malignancy. Indication-specific requirements (for example, prior bisphosphonate therapy, prior IV bisphosphonate for some Xgeva-lineage indications, and age thresholds) must be met as described in the medical necessity criteria.
Key Definitions and Thresholds
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.